Early-Stage Candidates for Primary Hyperparathyroidism and Thyroid Eye Disease Also Featured Crinetics' Founder & CEO, Scott Struthers Accepted John D. Baxter…
June 21, 2023Announcement no. 11 BioPorto A/S announces results of rights issue COPENHAGEN, Denmark and BOSTON, MA, USA, June 21,…
Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE)…
CINCINNATI, June 21, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology…
MELBOURNE, Australia and SAN FRANCISCO, June 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…
Change in Total Motor Score June 2023 Webcast Presentation Neurofilament Light Chain (Nfl) percentage change from baseline in Cerebrospinal Fluid…
With millions of Americans experiencing mental health symptoms, 23andMe+ members now have exclusive access to four mental health reports to…
Company is well-positioned to advance robust clinical-stage CNS pipeline, following oversubscribed Series B financing earlier this yearBASEL, Switzerland, June 21,…
JERSEY CITY, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to…
WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing…